Details
Stereochemistry | ACHIRAL |
Molecular Formula | C27H21F3N8O |
Molecular Weight | 530.5049 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cc1ccc(cc1Nc2nccc(-c3cnccn3)n2)C(=Nc4cc(cc(c4)-n5cc(C)nc5)C(F)(F)F)O
InChI
InChIKey=DUPWHXBITIZIKZ-UHFFFAOYSA-N
InChI=1S/C27H21F3N8O/c1-16-3-4-18(9-23(16)37-26-33-6-5-22(36-26)24-13-31-7-8-32-24)25(39)35-20-10-19(27(28,29)30)11-21(12-20)38-14-17(2)34-15-38/h3-15H,1-2H3,(H,35,39)(H,33,36,37)
Molecular Formula | C27H21F3N8O |
Molecular Weight | 530.5049 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24705186
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24705186
Radotinib (Supect) was developed and approved in Korea as a second-line Chronic Myeloid Leukemia treatment. The drug supresses cancer cells proliferation by inhibitiing BCR-ABL1 kinase which is a driver of Philadelphia chromosome-positive (Ph+) leukemia.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26666371
Take 300 mg or 400 mg twice daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26065685
Acute myeloid leukemia NB4, HL60, KASUMI-1 and THP-1 cells were incubated with various concentrations of radotinib (0, 1,10, and 100 uM) for 72 h at 37C. At 100 uM NB4 cells growth was inhibited to 18%.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 13:55:49 UTC 2021
by
admin
on
Sat Jun 26 13:55:49 UTC 2021
|
Record UNII |
I284LJY110
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1967
Created by
admin on Sat Jun 26 13:55:49 UTC 2021 , Edited by admin on Sat Jun 26 13:55:49 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB12323
Created by
admin on Sat Jun 26 13:55:49 UTC 2021 , Edited by admin on Sat Jun 26 13:55:49 UTC 2021
|
PRIMARY | |||
|
C98110
Created by
admin on Sat Jun 26 13:55:49 UTC 2021 , Edited by admin on Sat Jun 26 13:55:49 UTC 2021
|
PRIMARY | |||
|
5188
Created by
admin on Sat Jun 26 13:55:49 UTC 2021 , Edited by admin on Sat Jun 26 13:55:49 UTC 2021
|
PRIMARY | |||
|
9242
Created by
admin on Sat Jun 26 13:55:49 UTC 2021 , Edited by admin on Sat Jun 26 13:55:49 UTC 2021
|
PRIMARY | |||
|
926037-48-1
Created by
admin on Sat Jun 26 13:55:49 UTC 2021 , Edited by admin on Sat Jun 26 13:55:49 UTC 2021
|
PRIMARY | |||
|
7814
Created by
admin on Sat Jun 26 13:55:49 UTC 2021 , Edited by admin on Sat Jun 26 13:55:49 UTC 2021
|
PRIMARY | |||
|
SUB179788
Created by
admin on Sat Jun 26 13:55:49 UTC 2021 , Edited by admin on Sat Jun 26 13:55:49 UTC 2021
|
PRIMARY | |||
|
16063245
Created by
admin on Sat Jun 26 13:55:49 UTC 2021 , Edited by admin on Sat Jun 26 13:55:49 UTC 2021
|
PRIMARY | |||
|
Radotinib
Created by
admin on Sat Jun 26 13:55:49 UTC 2021 , Edited by admin on Sat Jun 26 13:55:49 UTC 2021
|
PRIMARY | |||
|
M11723
Created by
admin on Sat Jun 26 13:55:49 UTC 2021 , Edited by admin on Sat Jun 26 13:55:49 UTC 2021
|
PRIMARY | |||
|
I284LJY110
Created by
admin on Sat Jun 26 13:55:49 UTC 2021 , Edited by admin on Sat Jun 26 13:55:49 UTC 2021
|
PRIMARY | |||
|
926037-48-1
Created by
admin on Sat Jun 26 13:55:49 UTC 2021 , Edited by admin on Sat Jun 26 13:55:49 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |